

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Brignole Michele	
	Nothing to be declared (2015-2016-2017)
de Lange Frederik	
	Nothing to be declared (2015-2016-2017)
Deharo Jean-Claude	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Sanofi Aventis: Antiarrhythmic drugs (2015)
	- Meda pharma : Antiarrhythmic drugs (2015-2016)
	- Daiichi Sankyo : Anticoagulation (2015-2016)
	- Bayer Healthcare : Anticoagulation (2015-2016)
	- Spectranetics : Lead extraction (2015-2016)
	- Boehringer-Ingelheim : Oral anticoagulants (2015-2016)
	- Boston Scientific : PMs / ICDs (2015-2016)
	- Sorin Group : PMs / ICDs (2015-2016)
	- St Jude Medical : PMs / ICDs (2015-2016)
	- Biotronik : PMs / ICDs (2015-2016)
	- Medtronic : PMs / ICDs / Loop recorders (2015-2016)
	- Bristol Myers Squibb : anticoagulants (2015-2016-2017)
	- Boehringer-Ingelheim : Anticoagulants (2017)
	- Bayer Healthcare : Anticoagulants (2017)
	- Biotronik : CIEC (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Deharo Jean-Claude	- Abbott : CIED (2017)
	- Boston Scientific : CIED (2017)
	- Medtronic : CIED (2017)
	- Sorin Group : CIED (2017)
	D - Research funding (departmental or institutional) from healthcare industry Daiichi Sankyo : anticoagulants (2015-2016)
	- Bristol Myers Squibb : anticoagulants (2015-2016)
	- ¨Boehringer : anticoagulants (2015-2016)
	- Boston Scientific : PMs/ICDs (2015-2016)
	- Sorin Group : PMs/ICDs (2015-2016)
	- St Jude Medical : PMs/ICDs (2015-2016)
	- Medtronic : PMs/ICDs/Loop recorders (2015-2016)
	- Abbott : CIED (2017)
	- Boston Scientific : CIED (2017)
	- Sorin Group : CIED (2017)
	- Biotronik : CIED (2017)
	2- Other Positions of Influence
	 2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease. - no (2015)
	2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- no (2015)
	2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- no (2015)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Elliott Perry Mark	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - MyoKardia: Mutation guided therapies in cardiomyopathy (2015)
	- Amicus : Chaperone therapy for Fabry Disease (2015-2016-2017)
	- Shire HGT : Enzyme replacement therapy Fabry disease (2015-2016-2017)
	- Genzyme : Enzyme replacement therapy Fabry disease (2015-2016-2017)
	- Pfizer : Treatment for TTR amyloidosis (2015-2016-2017)
	- Idorsia : Treatment for Fabry Disease (2017)
	- Alnylam : Treatment for TTR amyloidosis (2017)
	D - Research funding (departmental or institutional) from healthcare industry Genzyme : Cardiac magenetic resonance imaging in HCM (2015-2016-2017)
	- Shire HGT : Clinical characterisation of Anderson-Fabry Disease (2015-2016-2017)
	- National Institute for Health and Clinical Excellence : Genetics of hypertrophic cardiomyopathy (2015-2016-2017)
	- British Heart Foundation : Hypertrophic cardiomyopathy (2015-2016-2017)
	2- Other Positions of Influence
	2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology Cardiomyopathy UK (2015-2016)
anciulli Alessandra	
	Nothing to be declared (2015-2016-2017)
edorowski Artur	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Cardiome: Brinavess (2015-2016-2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Fedorowski Artur	C - Receipt of royalties for intellectual property BRAHMS GmbH : biomarkers for syncope diagnostics (2017)
Furlan Raffaello	
	Nothing to be declared (2015-2016-2017)
Kenny Rose Anne	
	Nothing to be declared (2016-2017)
	1- Financial Declaration
	D - Research funding (departmental or institutional) from healthcare industry Medtronic : Reveal devices used for FUSE Study (2015)
Martin Alfonso	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer: Atrial fibrillation (2015-2016-2017)
	- Pfizer : Atrial Fibrillation (2015-2016-2017)
	- Boehringer Ingelheim: Atrial fibrillation (2015-2016-2017)
	- Daichii-Sankyo : Atrial fibrillation (2015-2016-2017)
Moya I Mitjans Angel	
	Nothing to be declared (2015-2016-2017)
Probst Vincent	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - LIvanova : ICD (2015) - Daiichi Sankyo : NACO (2015)
	- BMS : NACO (2015)
	- Boston Scientific : ICD (2015-2016-2017)

24/08/2018 4/40



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Probst Vincent	- Medtronic : ICD (2015-2016-2017)
	- Liva Nova : icd (2016-2017)
	- Biotronik : pm (2016-2017)
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : icd (2016-2017)
	E - Research funding (personal) Boston Scientific : ICD (2015)
Reed Matthew James	
	Nothing to be declared (2015-2016-2017)
Rice Ciara	
	Nothing to be declared (2015-2016-2017)
Sutton Richard	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic: Pacing (2015)
	- St Jude Medical : Speaker's Bureau - Academic writing (2015)
	- Abbott Vascular : St Jude Medical Speakers' Bureau for Scientific Writing (2016)
	- Medtronic : Syncope Consultancy (2016)
	- Medtronic : General (2017)
	- Abbott Laboratories : Member of Speakers' Bureau (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic: Syncope Prediction Study One payment for study (2015)
	D - Research funding (departmental or institutional) from healthcare industry Medtronic : Syncope Prediction: One Grant payment of £100k made last year. Study completed (2016)

24/08/2018 5/40



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Sutton Richard	2- Other Positions of Influence
	 2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease. - Shareholder in Boston Scientific whose products I do not use and for whom I do not consult or speak (2015)
	- Healthcare - OTHER - Shareholder in Device companies Boston Scientific and Edwards Lifesciences for whom I do not consult or speak. Shareholder in Pharma companies AstraZeneca, Shire and Roche for whom I do not consult or speak (2016)
	- Healthcare - INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY (2017)
	 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Shares held in Boston Scientific Inc, Edwards LifeSciences Laboratories, AstraZeneca PLC, Shire PLC, Roche SA. (2017)
Ungar Andrea	1- Financial Declaration
, and the second	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Edwards Lifesciences: Aortica valve (2015-2016)
	- Medtronic : Diagnostic and therapeutic device (2015-2016)
	- Medtronic : Long term monitoring (2017)
	2- Other Positions of Influence
	2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Gruppo Italiano Multidisciplinare per lo studio della sincope (GIMSI) Società Italiana Ipertensione arteriosa (SIIA) (2017)
van Dijk J Gert	
	Nothing to be declared (2015)
	1- Financial Declaration
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Finapress medical systems: Continuous Blood pressure measuremnet device (2016-2017)

24/08/2018 6/40



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Abdelali Salima	
	Nothing to be declared (2017)
Abdrakhmanov Ayan	
	Nothing to be declared (2017)
Aboyans Victor	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Amgen: Hyperlipidemia (2017)
	- Novartis : Hypertension (2017)
	- Boehringer-Ingelheim : Oral anticoagulation (2017)
	- Bayer Healthcare : Oral anticoagulation (2017)
	- Pfizer/BMS alliance : Oral anticoagulation (2017)
Agewall Stefan	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca: Antiplatelet treatment (2017)
Asteggiano Riccardo	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Edwards Lifesciences: TAVI valve (2017)
Baranowski Rafal	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic: none (2017)
	- Polpharma : none (2017)

24/08/2018 7/40



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Baranowski Rafal	- Servier : none (2017)
	- Bayer AG : none (2017)
	- Sandoz : none (2017)
	- Boehringer-Ingelheim : Pradaxa (2017)
Beinart Roy	
	Nothing to be declared (2017)
Ben Halima Afef	
	Nothing to be declared (2017)
Benlamin Hisham	
	Nothing to be declared (2017)
Bergfeldt Lennart	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Sanofi Aventis: Antiarrhythmic drug (2017)
Bertelli Luca	
	Nothing to be declared (2017)
Blanc Jean-Jacques	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Abbott: DEVICES (2017)
Bornstein Natan	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Pfizer Israel: Apixaban (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Type of Relationship with Industry
- Boehringer Ingelheim- Israel : Dabigatran (2017)
- EVER Neuro Pharma : Pharmaceutical Company (2017)
- Medtronic : Reveal (2017)
- Bayer-Israel : Rivaroxaban (2017)
D - Research funding (departmental or institutional) from healthcare industry Covidien : Medical Devices (2017)
- Stryker : Medical Devices (2017)
1- Financial Declaration
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic: Arrhythmias (ablation) (2017) - Sorin Group: Arrhythmias (ICD) (2017)
- Boston Scientific : Arrhythmias (S-ICD) (2017)
1- Financial Declaration
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Pfizer: Apixaban (2017)
- Bristol Myers Squibb : Apixaban (2017)
- Bayer : Aspirin, rivaroxaban (2017)
- MEDSCAPE-the heart.og : Inespecific (2017)
- Sanofi Aventis : PCSK9 inhibitors (2017)
- Novartis : Serelaxin, ACZ885, AHF Academy, (2017)
- Astra Zeneca : Ticagrelor (2017)
- Ferrer Internacional : Trinomia (polypill) (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca: Ticagrelor (2017)
	E - Research funding (personal) BMS: CV013-011 - STANDUP-AHF trial (2017)
	- Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)
	- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017)
	- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017)
	2- Other Positions of Influence
	 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. VP elect. Spanish Society of Cardiology FAHA (2017)
Burri Haran	
	Nothing to be declared (2017)
Chasnoits Alexandr	
	Nothing to be declared (2017)
Coca Antonio	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Merck Serono: Bisoprolol-Amlodipine (2017)
	- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2017)
	- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2017)
Collet Jean-Philippe	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bristol Myers Squibb: Lecture fees representing 2000 euros for 2017. (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	- Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017)
	- Bayer Healthcare: Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017)
	- Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) 2017)
	- Bayer AG: ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)
	- Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017)
	- Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
	- Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Costantino Giorgio	
	Nothing to be declared (2017)
Cunha Pedro Silva	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Llvanova: Cardiac ressynchronization therapy (2017)
	- Daiichi Sankyo : Edoxaban (2017)
Dan Gheorghe Andrei	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim: cardiology (2017)
	- Novartis : cardiology (2017)
	- Pfizer : Cardiology (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Dan Gheorghe Andrei	- Servier : cardiology (2017)
	- Alfa-Wassermann : cardiology (2017)
	- Bayer AG : cardiology (2017)
	- Roche Diagnostics : cardiology (2017)
	- Krka Pharma : cardiology (2017)
Deftereos Spyridon	1- Financial Declaration
	D - Research funding (departmental or institutional) from healthcare industry ELPEN Pharmaceutical Company: Antiarrhythmic pharmacotherapy (2017)
	- Medtronic : Cardiac Electrophysiology (2017)
	- Boston Scientific : Cardiac Electrophysiology and Interventional Cardiology (Coronaries) (2017)
Delgado Victoria	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott Vascular: Mitraclip (2017)
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : pacemakers (2017)
	- Medtronic : pacemakers (2017)
	- Biotronik : pacemakers (2017)
	- Edwards Lifesciences : valves (2017)
Diaz Infante Ernesto	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : Ablation catheter (2017)
	- Medtronic : Cardiac resynchronization therapy (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Dimmer Carlo	
	Nothing to be declared (2017)
Dolmans Faas	
	Nothing to be declared (2017)
Etsadashvili Kakhaber	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier: Perindopril, Ivabradine, (2017)
Fernandez Lozano Ignacio	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - St Jude Medical: AICD PM (2017)
Gaemperli Oliver	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - GE Healthcare: Imaging (2017)
Gajek Jacek	
	Nothing to be declared (2017)
Gudmundsson Kristjan	
	Nothing to be declared (2017)
Haugaa Kristina Hermann	1- Financial Declaration
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer: speaker fees (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hemels Martin	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim: Advisory Board fee, speakers fee/consultancy (2017)
	- Daiichi Sankyo : Advisory Board fee, speakers fee/consultancy (2017)
	- BMS/Pfizer : Advisory Board fee, speakers fee/consultancy (2017)
	- Biotronik : Speakers fee/consultancy (2017)
	- Bayer Netherlands : Speakers fee/consultancy (2017)
	- LIvanova : Speakers fee/consultancy (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim: Participation GLORIA AF study (2017)
Hindricks Gerhard	1- Financial Declaration
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : Pacemaker, Ablation (2017)
	- Biosense Webster : Pacemaker, Ablation (2017)
	- Biotronik : Pacemaker, catheter (2017)
	D - Research funding (departmental or institutional) from healthcare industry Abbott, Biotronik, Medtronic, Boston Scientific : Electropyhsiology, arrhythmias (2017)
	2- Other Positions of Influence
	 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Kalejs Oskars	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca: Cardiovascular Pharmacotherapy (2017)
	- Pfizer : Cardiovascular Pharmacotherapy (2017)
	- Abbott : Cardiovascular Pharmacotherapy. (2017)
	- Boehringer-Ingelheim : Cardiovascular Pharmacotherapy. (2017)
	- Novartis : Cardiovascular Pharmacotherapy. (2017)
	- Servier : Cardiovascular Pharmacotherapy. (2017)
	- Bayer AG : Cardiovascular Pharmacotherapy. (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Biosense Webster: Treatment of Atrial Fibrillation, Catheter Ablation (2017)
	D - Research funding (departmental or institutional) from healthcare industry Latvian Research Institute of Cardiology : Treatment of Heart Failure (2017)
Kautzner Josef	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Biosense Webster: catheters, mapping system (2017)
	- Bayer : drugs (2017)
	- Boehringer-Ingelheim : drugs (2017)
	- Daiichi Sankyo : drugs (2017)
	- Pfizer : drugs (2017)
	- Bayer Healthcare : drugs (2017)
	- Boston Scientific : pacemakers, ICDs (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Kautzner Josef	- Biotronik : pacemakers, ICDs, catheters (2017)
	- Liva nova (Sorin) : pacemakers, ICDs, catheters (2017)
	- Medtronic : pacemakers, ICDs, catheters, mapping system (2017)
	- St Jude Medical (Abbott) : pacemakers, ICDs, catheters, mapping system (2017)
Klingenheben Thomas	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Berlin Chemie AG: Angina treatment (2017)
	- Boehringer-Ingelheim : Anticoagulation (2017)
	- Bayer Vital : Anticoagulation (2017)
	- Bristol Myers Squibb : Antiplatelet therapy (2017)
Knuuti Juhani	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca: Consultancy for a research project for ischemic heart disease (2017)
	- Astra Zerieca : Consultancy for a research project for ischemic flear disease (2017) - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)
Kulakowski Piotr	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic: ablation (2017)
Lambrinou Ekaterini	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - TRAMA SOLUTIONS: Online course speaker fees (2017)
	- Novartis : Speaker fee and honorarium (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Leclercq Christophe	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott: devices (2017)
	- Boston Scientific : devices (2017)
	- Medtronic : devices (2017)
	- Biotronik : devices (2017)
	- LIvanova : devices (2017)
	D - Research funding (departmental or institutional) from healthcare industry Biotronik : devices (2017)
Lim Phang Boon	1- Financial Declaration
	D - Research funding (departmental or institutional) from healthcare industry Abbott : Atrial Fibrillation (2017)
Mabo Philippe	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Boehringer-Ingelheim: Anticoagulation (2017) - Bayer Healthcare: Anticoagulation (2017)
	- Bristol Myers Squibb : Anticoagulation (2017)
	- Meda pharma : Cardiac Arrhythmia (2017)
	- Abbott : CRM (2017)
	- Boston Scientific : CRM (2017)
	- Medtronic : CRM (2017)
	- Sorin Group : CRM (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Mabo Philippe	- Novartis : Heart failure (2017)
	D - Research funding (departmental or institutional) from healthcare industry Abbott : CRM (2017)
	- Boston Scientific : CRM (2017)
	- Medtronic : CRM (2017)
	- Sorin Group : CRM (2017)
	- Biotronik : CRM (2017)
Mirrakhimov Erkin	
	Nothing to be declared (2017)
Mitro Peter	
	Nothing to be declared (2017)
Molgaard Henning	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer: amyloidosis (2017)
	- Medtronic : Implantable loop recorders (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Pfizer: International Amyloidosis database - Thaos (2017)
Morillo Carlos Arturo	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic: Implantable Loop Recorders, AF Ablation (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer: Atrial Fibrillation App development (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Morillo Carlos Arturo	D - Research funding (departmental or institutional) from healthcare industry St Jude Medical : Atrial Fibrillation (2017)
	- Boston Scientific : ICD Teaching App (2017)
Nawar Moustafa	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer: NOAC's (2017)
	2- Other Positions of Influence
	 2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease. - Healthcare - ARRHYTHMIAS (2017)
Osswald Stefan	1- Financial Declaration
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : Devices (2017)
	- Biotronik : Devices (2017)
	- St. Jude Medical : Devices (2017)
	- Liva Nova : Devices (2017)
	- Abbott : Stents (2017)
	- Biosensors : Stents (2017)
Ozdemir Huseyin Murat	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer: Oral anticoagulants (2017)
	- Boehringer-Ingelheim : Oral anticoagulants (2017)
	- Daiichi Sankyo : Oral anticoagulants (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ozdemir Huseyin Murat	- Pfizer : Oral anticoagulants (2017)
	- Servier : perindopril (2017)
	- Astra Zeneca : Ticagrelor (2017)
Papasavvas Ilias	
	Nothing to be declared (2017)
Parikka Hannu	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer: Speaker fee (2017)
	- Bristol Myers Squibb : Speaker fee (2017)
	- St Jude Medical/Abbot : Speaker fee (2017)
	D - Research funding (departmental or institutional) from healthcare industry St Jude Medical/Abbot : Departmental research funding (2017)
Piepoli Massimo Francesco	
	Nothing to be declared (2017)
Piot Olivier	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer: direct oral anticoagulant (2017)
	- Boehringer-Ingelheim : direct oral anticoagulant (2017)
	- Bristol Myers Squibb : direct oral anticoagulant (2017)
	- Servier : ECG Monitoring (2017)
	- Zoll Medical : External defibrillator (2017)
	- LIvanova : pacemaker & ICD (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Piot Olivier	- Abbott : pacemaker, ICD, ablation catheter, LAA occluder (2017)
	- Biosense Webster : RF ablation (2017)
Puljevic Davor	2- Other Positions of Influence
	2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Member of HALMED comity for farmacovigilance (2017)
Puodziukynas Aras	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Pfizer: Apixaban (2017)
	- Boehringer-Ingelheim : Dabigatran (2017)
	- Bayer : Rivaroxaban (2017)
Raducan Aurica	
	Nothing to be declared (2017)
Raviele Antonio	
	Nothing to be declared (2017)
Roffi Marco	1- Financial Declaration
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : Stents (2017)
	- Medtronic : Stents (2017)
	- Biotronik : stents (2017)
	- Terumo Inc : stents (2017)
	- Abbott Vascular : stents (2017)

24/08/2018 21/40



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Roithinger Franz Xaver	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer: Anticoagulation (2017)
	- Boehringer-Ingelheim : Anticoagulation (2017)
	- Daiichi Sankyo : Anticoagulation (2017)
	- St. Jude Medical : Devices (2017)
	- Merck Ges m b H : Diabetes (2017)
	- Astra Zeneca : Platelet inhibition (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bristol Myers Squibb: Anticoagulation (2017)
	- Biotronik : Device Therapy (2017)
	- Biosense Webster : Electrophysiology (2017)
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : Electrophysiology (2017)
	- Astra Zeneca : Platelet inhibition (2017)
Saghy Laszlo	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Johnson & Johnson: catheter ablation (2017)
	- Medtronic : elctrophysiology (2017)
Sammut Mark Adrian	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : Devces (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Sammut Mark Adrian	- Medtronic : Devices (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : Devices (2017)
	- Medtronic : Devices (2017)
Shen Win-Kuang	
	Nothing to be declared (2017)
Simpson Iain A	2- Other Positions of Influence
	 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Stockburger Martin	
	Nothing to be declared (2017)
Traykov Vassil B	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Pfizer: Apixaban (2017)
	- Medtronic : Device therapy (2017)
	- Berlin Menarini : Ranolazine (2017)
	- Bayer AG : Rivaroxaban (2017)
	- Sandoz : Sotalol (2017)
Tyurina Tatiana	2- Other Positions of Influence
	2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Member of Russian Society of Cardiologist, Section - Syncopes (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Vanbrabant Peter	
	Nothing to be declared (2017)
Vandekerckhove Yves	1- Financial Declaration
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Johnson & Johnson : catheters (2017) - Abbott : devices (2017)
	- Boston Scientific : devices (2017)
	- Medtronic : devices (2017)
	- Astra Zeneca : pharma (2017)
	- Daiichi Sankyo : pharma (2017)
	- Bristol Myers Squibb : pharma (2017)
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : atrial fibrillation (2017)
	- Medtronic : atrial fibrillation (2017)
	- Johnson & Johnson : atrial fibrillation (2017)
Vavlukis Marija	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Jensen, Jensen: investigator (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Novo-Nordisk: consultancy (2017)
Vukmirovic Mihailo	
	Nothing to be declared (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer: afib (2017) - Pfizer: Afib (2017)

24/08/2018 25/40



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Aboyans Victor	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Amgen: Hyperlipidemia (2016-2017)
	- Novartis : Hypertension (2016-2017)
	- Boehringer-Ingelheim : Oral anticoagulation (2016-2017)
	- Bayer Healthcare : Oral anticoagulation (2016-2017)
	- Pfizer/BMS alliance : Oral anticoagulation (2016-2017)
Agewall Stefan	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca: Antiplatelet treatment (2016-2017)
Barbato Emanuele	1- Financial Declaration
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - St Jude Medical: Educational courses on FFR (2016)
	- Boston Scientific : Education courses on rotational atherectomy (2016-2017)
	- Abbott Vascular : Educational courses on FFR (2017)
	D - Research funding (departmental or institutional) from healthcare industry St Jude Medical : Unrestricted grant for an investigator-driven study (2016-2017)
Bueno Hector	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : BVS (2016)
	- Servier : ivabradine (2016)
	- Novartis : Serelaxin, ACZ885, AHF Academy (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	- Pfizer : Apixaban (2016-2017)
	- Bristol Myers Squibb : Apixaban (2016-2017)
	- Bayer : Aspirin, rivaroxaban (2016-2017)
	- MEDSCAPE-the heart.og : Inespecific (2016-2017)
	- Astra Zeneca : Ticagrelor (2016-2017)
	- Ferrer Internacional : Trinomia (polypill) (2016-2017)
	- Sanofi Aventis : PCSK9 inhibitors (2017)
	- Novartis : Serelaxin, ACZ885, AHF Academy, (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca: Ticagrelor (2016-2017)
	E - Research funding (personal) Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016)
	- BMS : CV013-011 - STANDUP-AHF trial (2016-2017)
	- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016-2017)
	- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016-2017)
	- Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)
	2- Other Positions of Influence
	2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- FAHA (2016)
	- VP elect. Spanish Society of Cardiology FAHA (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coca Antonio	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim: Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ 2016)
	- Merck Serono : Bisoprolol-Amlodipine (2016-2017)
	- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017)
	- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016-2017)
Collet Jean-Philippe	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - BMS: apixaban (2016)
	- Sanofi Aventis : CLOPIDOGREL (2016)
	- Medtronic : corevalve (2016)
	- Eli Lilly : PRASUGREL (2016)
	- Astra-Zeneca : ticagrelor (2016)
	- MSD : VORAPAXAR (2016)
	- Bayer Healthcare : xarelto (2016)
	- Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017)
	- Roche Diagnostics: Lecture fees representing 800 euros for 2017. (2017)
	- Bayer Healthcare: Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017)
	- Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)
	D - Research funding (departmental or institutional) from healthcare industry Bristol Myers Squibb : APIXABAN (2016)
	- Medtronic : COREVALVE (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	- Stago : LABORATORY TEST (2016)
	- Eli Lilly : PRASUGREL (2016)
	- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)
	- ICAN : THROMBOSIS (2016)
	- Astra Zeneca : TICAGRELOR (2016)
	- Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017)
	- Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)
	- Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017)
	- Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
	- Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Coman Ioan Mircea	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Daiichi Sankyo: anticoagulants (2016-2017)
	- Johnson & Johnson : antithrombotic (2016-2017)
	- Bayer AG : antithrombotic (2016-2017)
	- Sanofi Aventis : dyslipidemia (2016-2017)
	- Fournier Laboratories : dyslipidemia (2016-2017)
	- Amgen Inc : dyslipidemia , (2016-2017)
	- Novartis : HF (2016-2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	- Vifor International : iron deficiency (2016-2017)
	- Actelion : PHT (2016-2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Daiichi Sankyo: anticoagulants (2016-2017)
	- Johnson & Johnson : antithrombotic (2016-2017)
	- Bayer AG : antithrombotic (2016-2017)
	- Sanofi Aventis : dyslipidemia (2016-2017)
	- Amgen Inc : dyslipidemia (2016-2017)
	- Fournier Laboratories : dyslipidemia (2016-2017)
	- Novartis : HF (2016-2017)
	- Vifor International : iron deficiency (2016-2017)
	- Actelion : PHT (2016-2017)
Delgado Victoria	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott Vascular : Mitraclip (2016-2017)
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : Pacemaker-Heart failure (2016)
	- Medtronic : Pacemaker-Heart failure (2016)
	- Biotronik : Pacemaker-Heart Failure (2016)
	- Edwards Lifesciences : Valvular heart disease (2016)
	- Boston Scientific : pacemakers (2017)
	- Medtronic : pacemakers (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Delgado Victoria	- Biotronik : pacemakers (2017)
	- Edwards Lifesciences : valves (2017)
Fitzsimons Donna	
	Nothing to be declared (2016-2017)
Gaemperli Oliver	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - GE-Healthcare: Imaging (2016) - Amgen Inc: PCSK9 (2016)
	- Servier : Procorolan (2016)
	- GE Healthcare : Imaging (2017)
Hindricks Gerhard	1- Financial Declaration
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boston Scientific: CIEDs and interventional electrophysiology (2016)
	- St Jude Medical : CIEDs and interventional electrophysiology (2016)
	- Biotronik : CIEDs and interventional electrophysiology (2016)
	- Abbott : Pacemaker, Ablation (2017)
	- Biosense Webster : Pacemaker, Ablation (2017)
	- Biotronik : Pacemaker, catheter (2017)
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : CIEDs and interventional electrophysiology (2016)
	- St Jude Medical : CIEDs and interventional electrophysiology (2016)
	- Abbott, Biotronik, Medtronic, Boston Scientific : Electropyhsiology, arrhythmias (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hindricks Gerhard	2- Other Positions of Influence
	 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)
lung Bernard	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Edwards Lifesciences: Heart Valve Prostheses (2016-2017)
	- Boehringer Ingelheim : Anticoagulants (2017)
	- Novartis : Heart failure drugs (2017)
Juni Peter	
	Nothing to be declared (2016)
	1- Financial Declaration
	D - Research funding (departmental or institutional) from healthcare industry Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017)
	- Biosensors International Group : Drug-eluting stents (2017)
	- The Medicines Company : Thrombin inhibitors (2017)
	2- Other Positions of Influence
	2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Katus Hugo	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Daiichi Sankyo: Lixiana_NOAK (2016-2017)
	- Astra Zeneca : Ticagrelor (2016-2017)
	- Bayer Vital : Xarelto-NOAK (2016-2017)
	D - Research funding (departmental or institutional) from healthcare industry St Jude Medical : Biobank (2016-2017)
	- Philips : MRT (2016-2017)
Knuuti Juhani	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca: Consultancy for a research project for ischemic heart disease (2017)
	- GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)
	D - Research funding (departmental or institutional) from healthcare industry Orion : Brain diseases (2016)
	- AC Immune : Brain diseses (2016)
	- Antaros : Endocrinology (2016)
	- Boehringer-Ingelheim : Neurology (2016)
	- MSD : Neurology (2016)
	- GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - St Jude Medical: Echo course (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	- Servier : Ischemic Heart Disease (2016-2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic: Structural disease (2016)
	- Bayer : NOAC (2016-2017)
Leclercq Christophe	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry Sorin Group: devices (2016)
	- St Jude Medical : devices (2016)
	- Bayer Healthcare : DOAC (2016)
	- Boston Scientific : devices (2016-2017)
	- Medtronic : devices (2016-2017)
	- Biotronik : devices (2016-2017)
	- Abbott : devices (2017)
	- LIvanova : devices (2017)
	D - Research funding (departmental or institutional) from healthcare industry Biotronik : devices (2017)
McDonagh Theresa	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Vifor International: Ferrinject (2016-2017)
	- Novartis : Honoraria (2016-2017)
	- Bayer AG : Honoraria (2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	
	Nothing to be declared (2017)
	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier: Committee member, Speaker fee (2016)
	- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)
	- Amgen : Metabolic, Lipid (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Novartis: Heart Failure Prevention Initiatives (2016)
Ponikowski Piotr	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott Vascular : devices (2016)
	- BioControl : devices (2016)
	- Pfizer : lipids (2016)
	- Boehringer-Ingelheim : anticoagulant, diabetes (2016-2017)
	- Respicardia : devices (2016-2017)
	- Novartis : heart failure (2016-2017)
	- Cardiorentis : heart failure (2016-2017)
	- Berlin Chemie AG : heart failure (2016-2017)
	- Bayer Healthcare : heart failure (2016-2017)
	- Vifor Pharma ltd : heart failure (2016-2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ponikowski Piotr	- CIBIEM : heart failure (2016-2017)
	- Servier : heart failure, coronary artery disease (2016-2017)
	- Amgen : heart failure, lipids (2016-2017)
	- Pfizer : lipids, heart failure (2017)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - DC Device: devices (2016) - Cardiorentis: heart failure (2016)
	- Respicardia : anticoagulant (2016-2017)
	- BioControl : devices (2016-2017)
	- Novartis : heart failure (2016-2017)
	- Bayer Healthcare : heart failure (2016-2017)
	- CIBIEM : heart failure (2016-2017)
	- Servier : heart failure, coronary artery disease (2016-2017)
	- Amgen : heart failure, lipids (2016-2017)
	- Cardionomic : devices (2017)
	- Impuls Dynamics : devices (2017)
	- National Institute of Health : heart failure (2017)
	- European Union grant : heart failure, prevention (2017)
Richter Dimitrios	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Angelini : Lipids (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry	
Richter Dimitrios	- Swisspharma : lipids-hypertension (2016)	
	- Astra Zeneca : lipids-thrombosis (2016)	
	- Pfizer : lipids-thrombosis (2016)	
	- Winmedica : lipids-thrombosis (2016)	
	- Boehringer-Ingelheim : thrombosis (2016)	
	- Menarini : CAD- hypertension (2016-2017)	
	- Novartis : hypertension (2016-2017)	
	- Abbott : lipids (2016-2017)	
	- Amgen : lipids (2016-2017)	
	- Sanofi Aventis : Lipids (2016-2017)	
	- Lilly : Lipids (2016-2017)	
	- Unilever : lipids (2016-2017)	
	- Merck Sharp & Dohme : lipids (2016-2017)	
	- Vianex : lipids (2016-2017)	
	- Galenica : Lipids (2016-2017)	
	- Teva Pharmaceutical Industries : lipids, hypertension (2016-2017)	
	- Bayer Healthcare : Thrombosis (2016-2017)	
	- Edwards Lifesciences : aortic stenosis (2017)	
	- Novo-Nordisk : diabetes (2017)	
	- Unipharma : hypertension-thrombosis (2017)	



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Roffi Marco	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Terumo Inc: coronary catheters (2016)
	- Johnson & Johnson : coronary catheters (2016)
	- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016)
	D - Research funding (departmental or institutional) from healthcare industry Boston Scientific : devices (2016)
	- Medtronic : devices (2016)
	- Biotronik : devices (2016)
	- Terumo Inc : devices (2016)
	- Abbott Vascular : devices (2016)
	- Boston Scientific : Stents (2017)
	- Medtronic : Stents (2017)
	- Biotronik : stents (2017)
	- Terumo Inc : stents (2017)
	- Abbott Vascular : stents (2017)
Shlyakhto Evgeny	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Krka Pharma: Arterial Hypertension (2016-2017)
	- Novartis : Arterial Hypertension, Heart Failure (2016-2017)
	- Merck Sharp & Dohme : Atherosclerosis (2016-2017)
	- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	- Pfizer : General Cardiology (2016-2017)
Simpson Iain A	2- Other Positions of Influence
	 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2016-2017)
Sousa Uva Miguel	
	Nothing to be declared (2017)
	1- Financial Declaration
	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim: Dabigatran (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca: Ticagrelor (2016)
Windecker Stephan	1- Financial Declaration
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer AG: General Cardiology (2017)
	- Abbott : Invasive Cardiology (2017)
	- Boston Scientific : Invasive Cardiology (2017)
	- Edwards Lifesciences : invasive Cardiology (2017)
	D - Research funding (departmental or institutional) from healthcare industry St Jude Medical : General Cardiology (2016)
	- Terumo Inc : General Cardiology (2016)
	- Bracco Pharmaceutical : General Cardiology (2016)
	- Boston Scientific : General Cardiology (2016-2017)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	- Abbott : General Cardiology (2017)
	- St. Jude Medical : General Cardiology (2017)
	- Amgen Inc. : General Cardiology (2017)
	- Symetis SA : Invasive Cardiology (2017)
	- Biotronik : Invasive Cardiology (2017)
	- Terumo Inc : Invasive Cardiology (2017)
	2- Other Positions of Influence
	 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entreprenieur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Zamorano Gomez Jose	1- Financial Declaration
Luis	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Philips: 3D Echocardiography. (2016)
	- Servier : Clinical case presentation during ESC Cong 2016 (2016)
	- Pfizer : speaker CV risk factors. (2016)
	- MSD : speaker. CV risk factors (2016)
	- Bayer : afib (2017)
	- Pfizer : Afib (2017)
	D - Research funding (departmental or institutional) from healthcare industry Edwards Lifesciences: Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)
	- Abbott : Epidemiology study of Mitral regurgitation (2016)

24/08/2018 40/40